Speeches & presentations
Search through our archive of speeches and presentations from conferences and events.
Filter by
-
ViiV Healthcare analyst call
David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.
-
Cowen & Co. 39th Annual Health Care Conference, Boston
Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.
-
SVB Leerink Global Healthcare Conference, New York
Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.
-
Guggenheim Healthcare Talks Idea Forum, New York
Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.
-
37th annual JP Morgan Healthcare Conference, San Francisco
Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.
-
Analyst call on formation of new Consumer Healthcare JV
On Wednesday 19 December 2018, GSK announced an agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Brian McNamara, CEO GSK Consumer Healthcare and Simon Dingemans, Chief Financial Officer.
-
ViiV Meet the Management, London
David Redfern, Chairman ViiV Healthcare and Deborah Waterhouse, CEO ViiV Healthcare along with members of the ViiV Healthcare leadership team hosted a ViiV Healthcare Investor Event on Monday 10 December in London. The event included presentations from David, Deborah, Dr Kimberly Smith Global Research & Medical Strategy, Eric Dube Head of North America and Dr John Pottage Chief Scientific & Medical Officer and was followed by a Q&A session.
-
Citi 2018 Global Healthcare Conference, New York
Hal Barron, Chief Scientific Officer and President, R&D hosted a fireside chat at the Citi 2018 Global Healthcare Conference held in New York City on Wednesday 5 December, in which he provided an overview of GSK’s R&D priorities and progress made during 2018.
-
Analyst call on agreement to acquire TESARO
On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.
-
Evercore ISI HealthConX Conference, Boston
Deborah Waterhouse, CEO, and Dr Kimberly Smith, Head of Global Research and Medical Strategy, ViiV Healthcare, hosted a fireside chat at the Evercore ISI HealthConX Conference held in Boston, Massachusetts on Wednesday 28 November, during which they provided an overview of ViiV’s priorities and progress made during 2018.
-
Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR
On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.
-
Consumer Healthcare investor event, New Jersey
Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science, Consumer Sensory and R&D labs, as well as presentations from Brian McNamara, Marc Speichert, SVP Digital and Richard Slater, SVP R&D, followed by a Q&A session.
-
CECP CEO Investor Forum
Emma Walmsley, CEO, spoke at CECP’s CEO Investor Forum on Thursday 20 September 2018 about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.
Watch the webcast on YouTube -
Bank of America Merrill Lynch Global Healthcare Conference, London
Emma Walmsley, CEO, gave a presentation at the Bank of America Merrill Lynch Global Healthcare Conference in London on Thursday 13 September 2018 in which she provided an overview of GSK’s priorities and progress made during 2018.
-
GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update
On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.
The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.
-
Goldman Sachs 39th Annual Healthcare Conference, California
David Redfern, Chief Strategy Officer, hosted a fireside chat at the Goldman Sachs 39th Annual Healthcare Conference in Rancho Palos Verdes, California on Wednesday 13 June, in which he provided an overview of GSK’s priorities and progress made during 2018.
-
Jefferies 2018 Healthcare Conference, New York City
David Redfern, Chief Strategy Officer, hosted a fireside chat at the Jefferies 2018 Healthcare Conference in New York City on Wednesday 6 June, in which he provided an overview of GSK’s priorities and progress made during 2018.
-
Consumer Healthcare Update, London
On Tuesday, 27 March 2018, GSK reached an agreement with Novartis to acquire full ownership of the Consumer Healthcare business. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer and Brian McNamara, CEO, Consumer Healthcare.
-
36th annual JP Morgan Healthcare Conference, San Francisco, US
Emma Walmsley, CEO, gave a presentation at the 36th annual JP Morgan Healthcare Conference in San Francisco about our business outlook, as well as our latest product approvals and advances in our pipeline.
-
GSK Oncology Investor & Analyst Update
On Tuesday, 12 December 2017, GSK hosted an investor conference call following the presentation of scientific and clinical data on GSK2857916, GSK's anti-BCMA (B-cell Maturation Antigen) antibody-drug conjugate presented at the 59th American Society of Hematology (ASH) annual meeting.
The call was hosted by Luke Miels, President, GSK Global Pharmaceuticals and Axel Hoos, SVP and Therapy Area Head of Oncology R&D. The call also featured participation from an external expert in multiple myeloma.
